Canaccord Genuity began coverage of Castle Biosciences with a Buy rating and a $26 price target, while SVB Leerink assigned an Outperform rating and a $28 price target.
The case, which was originally being fought between Enzo and Hologic, was decided in favor of Becton Dickinson, Hologic's co-plaintiff.
Beyond its HostDx Sepsis test, the firm is working on a test to detect and differentiate bacterial from viral infections in patients presenting with fever.
The company recently launched an automated microbiology system in its Marlborough, Massachusetts laboratory using instruments from automation firm COPAN.
The FDA has granted accelerated approval to Rozlytrek as a treatment for adult and adolescent patients with NTRK fusion-positive cancers.
Industry players, faced with vague communications from the agency, scramble to decipher regulatory expectations and criticize the agency for trying to control PGx knowledge.
The firm's diagnostics and genomics group saw an 11 percent year-over-year revenue increase in the third quarter.
The immune sequencing firm is working on kit-ifying its two existing tests, as well as developing a second clinical test and expanding the label for clonoSeq.
By measuring and analyzing hospital testing operations, the firm anticipates helping its customers implement better antimicrobial stewardship programs.
The merger is aimed at expanding Salveo’s diagnostics capabilities and improving communication with providers and patients.